Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT03250351 Active, not recruiting - Clinical trials for Breast Cancer Female

Nerve Mobilization Techniques After Breast Cancer Surgery

Start date: December 2012
Phase: N/A
Study type: Interventional

Objective: to determine nerve mobilization techniques effectiveness at improving shoulder mobility and arm sensitive disorders in the early breast cancer postsurgical period with axillary lymph node dissection. Design: prospective randomized and single blind trial where participants will be randomly allocated into two groups by EPIDAT 3.1 software. Follow-up will be conducted through six physical therapy assessments: one before surgery, the second one after surgery, the third one post-physical therapy intervention, the fourth one after three months, the fifth after six months and, the sixth one after twelve months, and the seven one after 24 months. Participants: one hundred and forty women, who are undergoing a unilateral breast cancer surgery with axillary lymph node dissection in the Gynaecology and Obstetrics Unit from "Príncipe de Asturias" Hospital. Intervention: Early physical therapy to control group and Early physical therapy plus nerve mobilization to intervention group during the three following weeks from surgery. Hypothesis: nerve mobilization helps brachial plexus sliding among its interface which improves sensitive disorders, pain and functionality of the inner arm. Key outcomes: range of motion, pain, sensitive disorder, functionality, quality of life. Data analysis: quantitative variables through t-student test and qualitative variable though Chi test through by Statistical Package for the Social Sciences software.

NCT ID: NCT03250130 Recruiting - Breast Cancer Clinical Trials

Hypnosis for Patients Treated With Adjuvant Chemotherapy for Breast Cancer(HYPNOVAL)

Start date: June 2015
Phase: N/A
Study type: Interventional

The main objective is to assess the feasibility of an intervention based on medical Ericksonian hypnosis as a complementary therapy in patients treated with surgery after a diagnosis of breast cancer, followed by an indication of adjuvant chemotherapy and radiotherapy

NCT ID: NCT03249389 Completed - Breast Cancer Clinical Trials

Assessing the Changes in Markers of Calcium Vitamin Metabolism of for Breast Cancer Adjuvant (CALCIOBS)

Start date: October 2015
Phase: N/A
Study type: Interventional

This study is to Assess hypercalciuria between J1 of the cure and 1 J1 6 of the cure of adjuvant chemotherapy in patients receiving conventional adjuvant chemotherapy of breast cancer.

NCT ID: NCT03248492 Not yet recruiting - Breast Cancer Clinical Trials

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Start date: August 2017
Phase: Phase 2
Study type: Interventional

Some HER-2 breast cancer patients do not respond or build resistance to current treatment. DS-8201a is a new experimental product that is a combination of an antibody and a drug. It has not yet been approved for use. DS-8201a may slow down tumor growth. This might improve outcomes for these patients.

NCT ID: NCT03248427 Recruiting - Breast Cancer Clinical Trials

Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.

Start date: July 13, 2017
Phase: Phase 2
Study type: Interventional

CORALLEEN is a two-arm, randomized, multicentric study in postmenopausal women with primary HR+/HER2 negative Luminal B breast cancer that will explore if the combination of ribociclib with letrozole offers clinical benefit at least comparable to that of standard chemotherapy.

NCT ID: NCT03248258 Recruiting - Clinical trials for Decision Making ,Shared

Enhancing Shared Decision-Making in Metastatic Breast Cancer (Qualitative Study)

Start date: June 27, 2017
Phase: N/A
Study type: Observational

Develop a Metastatic Breast Cancer (MBC)-specific electronic Treatment Plans (TP). Aim 1a: Patient interviews along with navigator, nurse, and physician focus group discussions will be used to identify factors that influence decision-making in treatment selection and the optimal approach for sharing information about prognosis and guideline-based care. Identify decisional needs for Shared Decision Making (SDM) in MBC. Investigators will conduct semi-structured interviews/discussion groups with patients, navigators, nurses, and physicians to elements important to decision-making. Aim 1b: Develop MBC-specific TP. Investigators will build upon Aim1a to systematically develop the TP intervention using the Ottawa Decision Support Framework. Investigators will test the TPs with 5 patients and conduct qualitative investigations to refine the TP using an iterative process.

NCT ID: NCT03247478 Not yet recruiting - Clinical trials for Invasive Breast Cancer

Computed Tomography (CT) Reconstruction for Axillary Lymph Node Structure

Start date: August 15, 2017
Phase: N/A
Study type: Observational

This is a prospective, single-center, non-randomized, non-controlled observational study.

NCT ID: NCT03246009 Completed - Clinical trials for Chemotherapy-induced Neutropenia

Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients

Start date: January 21, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the tolerance and safety of the rHSA/GCSF in breast cancer patients with different doses and multiple injections. To observe the pharmacokinetic characteristics of recombinant human serum albumin /granulocyte colony-stimulating factor fusion protein after single and multiple administration

NCT ID: NCT03245112 Recruiting - Clinical trials for Metastatic Breast Cancer

Halaven Patient Registry (Metastatic Breast Cancer, MBC)

Start date: March 3, 2014
Phase: N/A
Study type: Observational [Patient Registry]

Since the first marketing authorization in the world in November 2010 granted by US FDA, Halaven has been approved for clinical use in more than 40 countries worldwide, including many Asian countries, e.g. Hong Kong, India, Japan, Malaysia, Myanmar, Philippines, South Korea, Singapore, Taiwan and Thailand. According to two large global phase III study reports of Halaven, very few Asian patients participated in these studies. In a phase II study of Halaven with metastatic breast cancer, the clinical efficacy and toxicity were reported only in 80 Japanese patients. Halaven has been granted its marketing authorization in Singapore since February 2011. However, most of other Asian countries including India have had the approval and launched from middle year of 2013 or in early 2014. Limited information of Halaven using in Asian patients are available except several case experience exchange presented by individual medical centers or as personal experience in the past. Some clinical concerns related to Halaven use are raised by clinicians during their clinical practice, such as how Halaven works on Asian patients, which type of patient obtains better clinical benefit from Halaven, and what are the main treatment related toxicities in Asian which may differ from Westerners due to potential ethnic diversity. Further understanding of Halaven related clinical benefit and toxicity in Asian patients through collecting clinical experience among Asian countries becomes necessary and may provide better information to anticipate these concerns. The proposed "Halaven Patient Registry" (called the "Registry") will be a patient population-based registry to collect therapeutic related information from patients with metastatic breast cancer who were treated with Halaven that was given as a clinical decision by patient's treating physician based on clinical status of a patient and proper indication of Halaven and to gain a better understanding of the use of Halaven in such Asian patients.

NCT ID: NCT03244943 Completed - Clinical trials for Periodontal Diseases

Cytokine Profiles in Breast Cancer Patients Undergoing Chemotherapy

Start date: August 1, 2015
Phase: N/A
Study type: Interventional

Aim: This study evaluated the effects of non-surgical periodontal therapy (NSPT) on the cytokine profile and the correlation to clinical parameters of patients undergoing chemotherapy for breast cancer. Materials and methods: 40 patients were allocated: Chronic periodontitis patients (PC) (n=20) and breast cancer with chronic periodontitis patients (CAN/PC) (n=20). The clinical parameters: probing depth (PD), clinical attachment level (CAL), plaque index (PI), gingival index (GI) and levels of IFN-γ, IL-4, IL-10, TGF-β, IL-17, IL-2, IL-6, IL-1β and TNF-α in gingival crevicular fluid (GCF) were evaluated at baseline, 45 and 180 days after therapy.